<?xml version="1.0" encoding="UTF-8"?>
<p>The best-known proteasome inhibitor is Bortezomib (Valcade) [
 <xref rid="B50-ijms-21-03622" ref-type="bibr">50</xref>], which was approved in 2008 as a first-line drug in the treatment of multiple myeloma. Other inhibitors are MG132, Lactacistin, Carfilzomib, Ixazomib and others which are able to target the 20S and 19S subunits (
 <xref ref-type="fig" rid="ijms-21-03622-f002">Figure 2</xref>) [
 <xref rid="B49-ijms-21-03622" ref-type="bibr">49</xref>,
 <xref rid="B52-ijms-21-03622" ref-type="bibr">52</xref>]. Interestingly, Computational Drug Repurposing Studies showed that Carfilzomib is a good candidate for the treatment of COVID-19 [
 <xref rid="B53-ijms-21-03622" ref-type="bibr">53</xref>].
</p>
